Serajuddin A T, Thakur A B, Ghoshal R N, Fakes M G, Ranadive S A, Morris K R, Varia S A
Pharmaceutics R&D Department, Bristol-Myers Squibb Pharmaceutical Research Institute, New Brunswick, New Jersey 08903, USA.
J Pharm Sci. 1999 Jul;88(7):696-704. doi: 10.1021/js980434g.
A drug-excipient compatibility screening model was developed by which potential stability problems due to interactions of drug substances with excipients in solid dosage forms can be predicted. The model involved storing drug-excipient blends with 20% added water in closed glass vials at 50 degrees C and analyzing them after 1 and 3 weeks for chemical and physical stability. The total weight of drug-excipient blend in a vial was usually kept at about 200 mg. The amount of drug substance in a blend was determined on the basis of the expected drug-to-excipient ratio in the final formulation. Potential roles of several key factors, such as the chemical nature of the excipient, drug-to-excipient ratio, moisture, microenvironmental pH of the drug-excipient mixture, temperature, and light, on dosage form stability could be identified by using the model. Certain physical changes, such as polymorphic conversion or change from crystalline to amorphous form, that could occur in drug-excipient mixtures were also studied. Selection of dosage form composition by using this model at the outset of a drug development program would lead to reduction of "surprise" problems during long-term stability testing of drug products.
建立了一种药物-辅料相容性筛选模型,通过该模型可以预测固体剂型中药物与辅料相互作用引起的潜在稳定性问题。该模型包括将添加了20%水的药物-辅料混合物密封在玻璃小瓶中,于50℃储存,并在1周和3周后对其进行化学和物理稳定性分析。小瓶中药物-辅料混合物的总重量通常保持在约200mg。混合物中药物的量根据最终制剂中预期的药物与辅料比例确定。通过使用该模型,可以确定几个关键因素,如辅料的化学性质、药物与辅料比例、水分、药物-辅料混合物的微环境pH值、温度和光照对剂型稳定性的潜在作用。还研究了药物-辅料混合物中可能发生的某些物理变化,如多晶型转变或从结晶形式变为无定形形式。在药物开发计划开始时使用该模型选择剂型组成,将减少药物产品长期稳定性测试期间出现“意外”问题的情况。